Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down - Should You Sell?

Key Points

• Ono Pharmaceutical's shares gapped down from $11.50 to $10.50 before market opening, with a last traded volume of 288 shares.
• The company reported a quarterly earnings miss of $0.26 per share, falling short of consensus estimates of $0.34, despite achieving revenues of $886.27 million.
• Ono Pharmaceutical has a market capitalization of $5.35 billion and a price-to-earnings ratio of 18.39, indicating relatively stable financial metrics.

Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) shares gapped down before the market opened on Tuesday . The stock had previously closed at $11.50, but opened at $10.50. Ono Pharmaceutical shares last traded at $10.50, with a volume of 288 shares trading hands.

Ono Pharmaceutical Stock Performance

The stock's fifty day moving average is $10.60 and its two-hundred day moving average is $10.71. The firm has a market capitalization of $5.35 billion, a price-to-earnings ratio of 18.39 and a beta of 0.51. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.56 and a current ratio of 3.07.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.34 by ($0.08). The firm had revenue of $886.27 million for the quarter, compared to the consensus estimate of $827.29 million. Ono Pharmaceutical had a return on equity of 5.49% and a net margin of 8.75%.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.